UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2025
Commission File Number: 002-023311
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On April 21, 2025, Ascentage Pharma Group International issued a Hong Kong Stock Exchange voluntary announcement entitled “ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX AND OLVEREMBATINIB IN CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) 2025 GUIDELINES”.
A copy of the Hong Kong Stock Exchange voluntary announcement is attached as Exhibit 99.1 to this Form 6-K and is incorporated by reference herein.
1
INDEX TO EXHIBITS
| Exhibit Number | Exhibit Title | |
| 99.1 | Hong Kong Stock Exchange voluntary announcement dated April 21, 2025 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | ||
| Date: April 21, 2025 | /s/ Dajun Yang | |
| Name: | Dajun Yang | |
| Title: | Chief Executive Officer | |
3